Evaluation of a Single-Dose Nucleoside-Modified Messenger RNA Vaccine Encoding Hendra Virus-Soluble Glycoprotein Against Lethal Nipah virus Challenge in Syrian Hamsters. (21st November 2019)

• Record Type: Journal Article
• Authors: Lo, Michael K; Spengler, Jessica R; Welch, Stephen R; Harmon, Jessica R; Coleman-McCray, JoAnn D; Scholte, Florine E M; Shrivastava-Ranjan, Punya; Montgomery, Joel M; Nichol, Stuart T; Weissman, Drew; Spiropoulou, Christina F
• Is Part Of: Journal of infectious diseases. Volume 221(2020)Supplement 4
• Page Start: S493
• Page End: S498
• Publication Date: 2019-11-21
• Subjects: Nipah virus -- mRNA vaccine -- soluble Hendra virus glycoprotein -- virus -- hemorrhagic fever -- Syrian hamster -- disease -- lung -- brain -- CNS -- neurological -- respiratory; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiz553
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: In the absence of approved vaccines and therapeutics for use in humans, Nipah virus (NiV) continues to cause fatal outbreaks of encephalitis and respiratory disease in Bangladesh and India on a near-annual basis. We determined that a single dose of a lipid nanoparticle nucleoside-modified messenger RNA vaccine encoding the soluble Hendra virus glycoprotein protected up to 70% of Syrian hamsters from lethal NiV challenge, despite animals having suboptimally primed immune responses before challenge. These data provide a foundation from which to optimize future messenger RNA vaccination studies against NiV and other highly pathogenic viruses.